Moderna and Merck's mRNA cancer vaccine shows promise in reducing risk of melanoma relapse.
TL;DR
Moderna and Merck plan to launch a Phase III study this year for their personalized cancer vaccine in melanoma, and have revealed more details from a Phase IIb test that earlier this year renewed excitement about the use of vaccines in fighting tumors. AstraZeneca posted event-free survival data on Imfinzi’s use before and after surgery in patients with non-small cell lung cancer on Sunday, with its rival Merck months away from an FDA decision in the same indication.
- Moderna and Merck prepare for PhIII trial of cancer vaccine, and an expansion to lung cancer: #AACR23 Endpoints News
- In what could be a 'big shift' for cancer treatment, mRNA vaccine shows promise against melanoma USA TODAY
- mRNA cancer vaccine an 'exciting' advance in reducing risk of melanoma relapse, trial shows Yahoo News
- AACR: Merck, Moderna plan for phase 3 cancer vax trial in '23 FierceBiotech
- Moderna, Merck Show Progress Toward Cancer Vaccines The Wall Street Journal
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News